糖尿病视网膜病变十年发病率及安全筛查间隔评估:OPHDIAT研究
结果显示1型和2型糖尿病十年累积发病率分别为19.10%和17.03%,基线无病变者安全筛查间隔分别为2.2年和3.0年,低风险2型糖尿病患者为4.2年。
要点
- 1型糖尿病基线无视网膜病变者十年可转诊病变累积发病率为19.10%。
- 2型糖尿病基线无视网膜病变者十年可转诊病变累积发病率为17.03%。
- 基线无病变者安全筛查间隔:1型2.2年、2型3.0年、低风险2型4.2年。
核心结论
- 在巴黎地区,基线无视网膜病变的1型糖尿病、2型糖尿病和低风险2型糖尿病患者,分别采用2年、3年和4年筛查间隔被认为是安全的。
研究设计与样本
- 观察性、前瞻性、多中心研究,2004年6月至2017年9月基于巴黎地区糖尿病视网膜病变区域筛查项目。
- 采用Turnbull生存估计量计算基线无视网膜病变者的可转诊糖尿病视网膜病变发病率。
主要发现
- 1型糖尿病十年可转诊糖尿病视网膜病变累积发病率为19.10%(95%CI 17.21%至21.14%)。
- 2型糖尿病十年可转诊糖尿病视网膜病变累积发病率为17.03%(95%CI 15.78%至18.35%)。
- 基线无糖尿病视网膜病变者安全筛查间隔:1型糖尿病2.2年(95%CI 2.0至2.4),2型糖尿病3.0年(95%CI 2.9至3.1)。
- 低风险2型糖尿病亚组安全筛查间隔为4.2年(95%CI 3.8至4.6)。
关键数值与推荐
- 安全筛查间隔定义为保持无可转诊糖尿病视网膜病变的概率为95%。
- 1型糖尿病基线无病变者安全筛查间隔2.2年(95%CI 2.0至2.4)。
- 2型糖尿病基线无病变者安全筛查间隔3.0年(95%CI 2.9至3.1)。
- 低风险2型糖尿病基线无病变者安全筛查间隔4.2年(95%CI 3.8至4.6)。
临床怎么用
- 对于基线无视网膜病变的1型糖尿病患者,可考虑将筛查间隔延长至约2年。
- 对于基线无视网膜病变的2型糖尿病患者,可考虑将筛查间隔延长至约3年。
- 对于低风险2型糖尿病且基线无视网膜病变者,可考虑将筛查间隔延长至约4年。
- 上述数据可支持考虑延长筛查间隔,但需随机临床试验确认安全性。
局限性
- 研究数据来自巴黎地区,外推至其他地区需谨慎。
- 作者指出需随机临床试验确认延长筛查间隔对糖尿病患者的安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To estimate the 10-year incidence of referable diabetic retinopathy (DR) in a French population with type 1 and 2 diabetes mellitus (DM). A secondary objective was the assessment of safe screening intervals in patients with diabetes without retinopathy. METHODS: Observational, prospective and multicentric study between June 2004 and September 2017 based on a regional screening programme for DR in the Paris region. The incidence of referable DR in patients without retinopathy at baseline was calculated by the Turnbull survival estimator. A safe screening interval was defined as a 95% probability of remaining without referable DR. RESULTS: Among the 25 745 participants with type 1 (n=6086) or type 2 (n=19 659) DM, the 10-year cumulative incidence of referable DR was 19.10% (95% CI 17.21% to 21.14%) and 17.03% (15.78% to 18.35%), median (IQR) follow-up=3.33 (4.24) years. The safe screening interval for patients without DR at the first examination for type 1 and 2 DM was 2.2 (95% CI 2.0 to 2.4) and 3.0 (2.9 to 3.1) years, respectively. In a subgroup of low-risk patients with type 2 DM, the safe screening interval was 4.2 (3.8 to 4.6) years. CONCLUSIONS: These data suggest that in Paris area, a 2-year, 3-year and 4-year screening interval was considered safe for type 1 DM, type 2 DM and for low-risk patients with type 2 DM, respectively, without DR at the first examination. While these data might be used to support the consideration of extending screening intervals, a randomised clinical trial would be suitable to confirm the safety for patients with DM.
引用
- Chamard C, Daien V, Erginay A, et al. Ten-year incidence and assessment of safe screening intervals for diabetic retinopathy: the OPHDIAT study. Br J Ophthalmol. 2020. PMID: 32522790. doi:10.1136/bjophthalmol-2020-316030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。